1558 — Yichang Hec Changjiang Pharmaceutical Co Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- HK$13.97bn
- HK$14.88bn
- CNY3.72bn
Brief: YiChang Hec Changjiang Pharmaceutical Says As At Sept 30, Loss Attributable RMB415.0 Mln
Brief: Yichang Hec Changjiang Pharmaceutical Says Insulin Glargine Injection Approved To Launch By NMPA
Brief: Yichang HEC Changjiang Pharmaceutical Says Controlling Shareholder Intends To Transfer About 452.4 Million Shares In Co
Brief: Yichang Hec Changjiang Pharmaceutical Posts HY Revenue Rmb202.2 MLN
Brief: Yichang Hec Changjiang Pharmaceutical Sees Net Loss Attributable Ranging From Rmb494 Mln To Rmb556 Mln For HY
Hong Kong-listed YiChang HEC hits record low on weak earnings outlook
Brief: Yichang Hec Changjiang Pharmaceutical Sees HY Net Profit Attributable To Decrease
China's YiChang HEC hits three-month high on drug launch approval
Brief: Yichang Hec Changjiang Pharmaceutical Says Atorvastatin Calcium Tablets Approved To Launch
HK-listed YiChang HEC rises most in 3 months on robust sales outlook
Brief: Yichang Hec Changjiang Pharma Says Tablets Won Bid For Centralized Procurement
Brief: Yichang Hec Changjiang Pharmaceutical Announces Rivaroxaban Tablets Approved To Launch By Nmpa
Brief: Yichang Hec Changjiang Pharmaceutical Says Aripiprazole Tablets Approved For Launch
Brief: Yichang Hec Changjiang Pharmaceutical Announces Febuxostat Tablets Approved To Launch From Nmpa
Brief: Yichang Hec Changjiang Pharmaceutical Says QTRLY Operating Revenue Rmb102.4 Mln VS Rmb2.01 Bln
Brief: Yichang Hec Changjiang Pharma Says ot Approval To Launch Escitalopram Oxalate Tablets
Brief: Yichang HEC ChangJiang Pharmaceutical Posts FY Revenue RMB2,348.11 Mln
Brief: Yichang Hec Changjiang Pharmaceutical Receives NMPA Approval Related To Registration For Domestic Production Of Insulin Aspart 30 Injection
Brief: Yichang HEC Changjiang Pharmaceutical Says Apixaban Tablets Obtained Approval For Launch From China NMPA